Viridian Therapeutics (NASDAQ:VRDN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (NASDAQ:VRDN) had its price target lowered by analysts at Truist Financial Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]